IceCure (ICCM) VP Tel‑Tzure Bussi Receives 101,483 RSUs

What Happened

• Tel‑Tzure Tlalit Bussi, VP, Business Development & Global Marketing at IceCure Medical Ltd. (ICCM), received a grant of 101,483 restricted share units (RSUs) on August 14, 2026. The reported acquisition price was $0.00 (non‑cash compensation).
• The 101,483 RSUs vest 25% on August 11, 2027, with the remaining 75% vesting in twelve equal quarterly installments of 6.25% each. This award adds to prior RSU grants, bringing total outstanding RSUs granted to her to 106,518 (101,483 new + 5,035 prior RSUs), plus 653 ordinary shares.

Key Details

• Transaction date: August 14, 2026; Filing date (Form 4): August 17, 2026.
• Price: $0.00 (award/grant — non‑cash).
• Holdings after transaction (reported): 653 ordinary shares and 106,518 RSUs (101,483 newly granted + 2,273 + 1,733 + 1,029 prior RSUs). Note: 25% of the 2,273 RSU tranche vested on July 29, 2026; all other listed RSUs remained unvested as of August 13, 2026.
• Footnotes: All holdings in clauses (ii)–(v) are adjusted for the issuer’s 1‑for‑30 reverse share split. Vesting schedules for earlier grants follow the same 25% at one year then quarterly structure.
• Filing status: Reported on Form 4 with transaction date Aug 14, 2026 (no late‑filing indication in the report).

Context

• This was an equity compensation grant (code A), not an open‑market purchase or sale; such awards are standard executive/employee compensation and do not by themselves indicate a buying or selling signal.
• The new RSUs are largely unvested and will convert to shares only as they vest per the schedule above.